Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688513 Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
93 GF Score
Price ¥54.63
GF Value ¥48.10
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Chengdu Easton Biopharmaceuticals Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Chengdu Easton Biopharmaceuticals Co Valuation Rank Related Terms

SHSE:688513
93GF Score
Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued. The current stock price of ¥54.63 is trading 13.6% above its estimated GF Value™ of ¥48.10. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.

Key valuation signals for SHSE:688513:

  • Valuation Rank:
  • GF Value™: ¥48.10 vs. price of ¥54.63 (13.6% above fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Easton Biopharmaceuticals Co Business Description

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
93GF Score

Get the complete analysis for SHSE:688513

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥54.63
Price
¥48.10
GF Value